EP3684336A4 - Methods and compositions for the treatment of epidermolysis bullosa - Google Patents

Methods and compositions for the treatment of epidermolysis bullosa Download PDF

Info

Publication number
EP3684336A4
EP3684336A4 EP18859166.3A EP18859166A EP3684336A4 EP 3684336 A4 EP3684336 A4 EP 3684336A4 EP 18859166 A EP18859166 A EP 18859166A EP 3684336 A4 EP3684336 A4 EP 3684336A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
epidermolysis bullosa
bullosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18859166.3A
Other languages
German (de)
French (fr)
Other versions
EP3684336A1 (en
Inventor
Evangelos V. BADIAVAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/712,294 external-priority patent/US20180104186A1/en
Application filed by University of Miami filed Critical University of Miami
Publication of EP3684336A1 publication Critical patent/EP3684336A1/en
Publication of EP3684336A4 publication Critical patent/EP3684336A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Water Treatments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP18859166.3A 2017-09-22 2018-09-21 Methods and compositions for the treatment of epidermolysis bullosa Pending EP3684336A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/712,294 US20180104186A1 (en) 2013-03-13 2017-09-22 Methods and compositions for the treatment of epidermolysis bullosa
PCT/US2018/052213 WO2019060719A1 (en) 2017-09-22 2018-09-21 Methods and compositions for the treatment of epidermolysis bullosa

Publications (2)

Publication Number Publication Date
EP3684336A1 EP3684336A1 (en) 2020-07-29
EP3684336A4 true EP3684336A4 (en) 2021-06-02

Family

ID=65810503

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18859166.3A Pending EP3684336A4 (en) 2017-09-22 2018-09-21 Methods and compositions for the treatment of epidermolysis bullosa

Country Status (10)

Country Link
EP (1) EP3684336A4 (en)
JP (1) JP2020534344A (en)
KR (1) KR20200088799A (en)
CN (1) CN111182890A (en)
AU (1) AU2018335788A1 (en)
CA (1) CA3076610A1 (en)
EA (1) EA202090814A1 (en)
IL (1) IL273407A (en)
MX (2) MX2020002777A (en)
WO (1) WO2019060719A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
KR102125567B1 (en) * 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 Large-Scale Production of Plant Derived Exosomes
WO2022018884A1 (en) * 2020-07-22 2022-01-27 国立大学法人大阪大学 Therapeutic agent for dystrophic epidermolysis bullosa
JP2023538109A (en) * 2020-08-21 2023-09-06 ユニバーシティ オブ マイアミ Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
EP3971440B1 (en) 2020-09-21 2023-12-27 Brembo S.p.A. Braking band of a disc brake disc and disc brake disc
CA3228644A1 (en) * 2021-08-12 2023-02-16 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
CA3234557A1 (en) * 2021-10-12 2023-04-20 Armen A. Karamanian Methods of treating epidermolysis bullosa with cell-free amniotic fluid compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138878A1 (en) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
WO2017123022A1 (en) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 Stem cell-derived exosome containing high amount of growth factors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10500231B2 (en) * 2013-03-13 2019-12-10 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US20160220613A1 (en) * 2013-09-16 2016-08-04 Agency For Science, Technology And Research Method
WO2016172598A1 (en) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
WO2017122095A1 (en) * 2016-01-15 2017-07-20 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138878A1 (en) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
WO2017123022A1 (en) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 Stem cell-derived exosome containing high amount of growth factors
US20190133922A1 (en) * 2016-01-12 2019-05-09 Kangstem Biotech Co., Ltd. Stem Cell-Derived Exosomes Containing a High Amount of Growth Factors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DINH HA ET AL: "Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges", ACTA PHARMACEUTICA SINICA B, vol. 6, no. 4, 1 July 2016 (2016-07-01), pages 287 - 296, XP055303644, ISSN: 2211-3835, DOI: 10.1016/j.apsb.2016.02.001 *
See also references of WO2019060719A1 *

Also Published As

Publication number Publication date
KR20200088799A (en) 2020-07-23
EA202090814A1 (en) 2020-08-07
WO2019060719A1 (en) 2019-03-28
MX2020002777A (en) 2020-09-17
CN111182890A (en) 2020-05-19
EP3684336A1 (en) 2020-07-29
IL273407A (en) 2020-05-31
JP2020534344A (en) 2020-11-26
AU2018335788A1 (en) 2020-03-19
MX2022015753A (en) 2023-01-19
CA3076610A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
EP3675882A4 (en) Methods and compositions for treatment of microbiome-associated disorders
EP3684336A4 (en) Methods and compositions for the treatment of epidermolysis bullosa
EP3347469A4 (en) Methods and compositions for the treatment of glaucoma
EP3426250A4 (en) Methods of treatment
EP3607072A4 (en) Compositions and methods for treating phenylketonuria
EP3373951A4 (en) Methods and compositions for the treatment of epidermolysis bullosa
EP3630072A4 (en) Methods and compositions for treating excessive sleepiness
EP3408344A4 (en) Well treatment methods and compositions
EP3602606A4 (en) Surface treatment methods and compositions therefor
EP3585817A4 (en) Compositions and methods for treatment of cancer
EP3217795A4 (en) Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
EP3538189A4 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
EP3448421A4 (en) Methods and compositions for the prevention and treatment of surgical adhesions
EP3720421A4 (en) Compositions and methods for the treatment of metabolic conditions
EP3310783A4 (en) Methods and compositions for the prevention and treatment of hearing loss
EP3634422A4 (en) Methods of treating leukodystrophies
EP3429584A4 (en) Compositions and methods for the treatment of presbyopia
EP3643316A4 (en) Treatment agent for epidermolysis bullosa
EP3368048A4 (en) Methods and compositions for the treatment of amyloidosis
EP3423064A4 (en) Formulations of testosterone and methods of treatment therewith
EP3452044A4 (en) Compositions and methods for the treatment of cancer
EP3341006A4 (en) Compositions and methods for the treatment of neurodamage
EP3373922A4 (en) Compositions and methods for treatment of homocystinuria
EP3349719A4 (en) Compositions and methods for the treatment and prevention of radiation dermatitis
EP3568020A4 (en) Compositions and methods for the treatment of demyelinating conditions

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200422

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031789

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/127 20060101AFI20210429BHEP

Ipc: A61K 35/28 20150101ALI20210429BHEP

Ipc: A61Q 19/00 20060101ALI20210429BHEP

Ipc: A61P 17/00 20060101ALI20210429BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601